Anti-Mouse IFNAR-1 – Purified In vivo GOLD™ Functional Grade

Pricing & Details

Product No.I-401
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
CD118, Ifar, Ifnar, Ifrc, INF-a receptor, Interferon-α/β receptor α chain precursor
Prod No.
Add to cart
I-401-1.0 mg
1.0 mg
In stock
Min: 1
Step: 1
I-401-5.0 mg
5.0 mg
In stock
Min: 1
Step: 1
I-401-25 mg
25 mg
In stock
Min: 1
Step: 1
I-401-50 mg
50 mg
In stock
Min: 1
Step: 1
I-401-100 mg
100 mg
In stock
Min: 1
Step: 1


Antibody Details

Product Details

Reactivity Species
Host Species
This antibody was produced by In vivo genetic immunization of IFNAR1 knockout mice with a plasmid encoding the extracellular domain of murine IFNAR1.
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
<1.0 EU/µg as determined by the LAL method
≥95% monomer by analytical SEC
>95% by SDS Page
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for clone MAR1-5A3 antibody for staining cells in flow cytometry is ≤ 2.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application. NOTE: Leinco Technologies suggests using Anti-Mouse IFNAR1-Biotin (With Streptavidin - PE; Part No. S211) (Leinco Product No.: I-402) for flow cytometry of mouse cells
Other Applications Reported In Literature ?
B Clone MAR1-5A3 has a short half-life due to the rapid recycling of cells that express the IFNAR1 receptor. In order to block function In vivo, continual blocking of all compartments is necessary. Therefore, a large loading dose is necessary to saturate all In vivo binding sites and should be maintained to ensure binding site saturation. For In vivo blocking studies, a loading dose of 2.5 mg/mouse, followed by a weekly dose of 0.5 mg/mouse is recommended. The half-life following a 2.5 mg loading dose is approximately 5 days. However, if you fail to saturate the binding sites by injecting a low dose of 250 μg, for example, the half life is only 1.5 days.
WB For Western blotting, the suggested use of this reagent is 1.0 µg per ml (See Data Results) IP
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


Clone MAR1-5A3 recognizes an epitope on mouse IFNAR1.
Antigen Distribution
IFNAR1 and IFNAR2 are coexpressed on nearly all cells.
IFNAR1 is a type I membrane protein, that in conjunction with IFNAR2, makes up the heterodimeric receptor that binds all type I IFNs, which includes IFN α and β. Binding and activation of the receptor stimulates Janus protein kinases, which leads to the phosphorylation of several other proteins, namely STAT1 and STAT2. IFNAR1 has also been shown to interact with PRMT1 and Tyrosine kinase 2. Type I IFNs are a family of cytokines that have been shown to promote anti-viral, anti-microbial, anti-tumor and autoimmune responses In vivo.

Antigen Details

NCBI Gene Bank ID

References & Citations

1.) Beaver, Jacob T. et al. (2020) Human Vaccines & Immunotherapeutics 16:9, 2092-2108 Article Link
2.) Theofilopoulos, AN. et al. (2012) J Immunol. 189: 000–000. Article Link
3.) Oldstone, Michael B. A. et al. (2017) Proc Natl Acad Sci U S A. 114(14): 3708–3713. PubMed
4.) Schreiber, RD et al. (2015) PLoS One.10(5):e0128636PubMed
5.) Shin, Haina et al. (2018) J Virol. 92(7): e00038-18. PubMed
6.) Crack, Peter J. et al. (2016) eNeuro 10.1523/ENEURO.0128-15.2016 Article Link
7.) Sheehan, K. C. F. et al. (2006) JICR 26(11):804
8.) Dunn, G. P. et al. (2005) Nat. Immunol. 6(7):722
9.) Fenner, J. E. et al. (2006) Nat. Immunol. 7(1):33
10). Biron, C. A. et al. (2007) J Exp Med. 204(10): 2383
11.) Raju et al. (2019) Cell Reports. 29:2556–2564 Journal Link
12.) Ortiz et al. (2019) Cancer Cell. 35:33–45 Journal Link
13.) Case et al. (2020) Cell Host & Microbe. 28:465–474 Journal Link
14.) Hassan et al. (2020) Cell. 183:169–184 Journal Link
15.) Hassan et al. (2020) Cell. 182:744–753 Journal Link
16.) Stine et al. (2019) Cell Stem Cell. 25:830–845 Journal Link
17.) White et al. (2018) Cell. 175:1198–1212 Journal Link
18.) Jagger et al. (2017) Cell Host & Microbe. 22:366–376 Journal Link
19.) Richner et al. (2017) Cell. 170:273–283 Journal Link
20.) Richner et al. (2017) Cell. 168:1114–1125 Journal Link
Elisa Sandwich Protocol
Flow Cytometry
Immunoprecipitation Protocol
General Western Blot Protocol

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Cookie Policy
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy.